ZVSAOTCPharmaceutical PreparationsUS GAAP · USD

ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for inflammatory and renal diseases. Its business centers on drug candidates and related intellectual property rather than commercialized products, with operations organized around research, development, and clinical-stage advancement.

Ask about the company
Operating profit (EBIT)-25.5m USD
−179.0 %y/y
Net income-25.0m USD
−165.1 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-125-100-75-50-250m USD2021: EBIT -0.24 m USD20212022: EBIT -0.82 m USD20222023: EBIT -108 m USD20232024: EBIT -9.1 m USD20242025: EBIT -25 m USD2025-25
RevenueOperating profit (EBIT)

Business

Share of revenue
Inflammatory disease therapeutics50 %

Drug candidates and development programs targeting inflammatory pathways and related disorders.

Renal disease therapeutics30 %

Research and development programs focused on kidney and renal-related diseases.

Intellectual property and pipeline assets20 %

Patents, formulations, and other proprietary assets supporting the development pipeline.

Customers

ZyVersa does not appear to sell commercial products to end customers in the traditional sense; its economic counterparties are primarily investors, research partners, and future healthcare market participants. In a development-stage model, the eventual buyers of approved therapies would be hospitals, physicians, specialty pharmacies, and payers, but current activity is centered on advancing candidates toward those markets.

Capital providers

Equity investors and financing counterparties that fund the company’s development programs and corporate operations.

Research collaborators

Scientific and development partners that may support preclinical or clinical work on pipeline assets.

Future healthcare customers

Hospitals, physicians, specialty pharmacies, and payers that would buy approved therapies if programs succeed.

Strategy

The company’s strategic focus is to advance its therapeutic pipeline through research, development, and clinical validation. For a small biopharmaceutical issuer, progress on scientific milestones, financing access, and regulatory execution are central to building value and preserving optionality for partnering or commercialization.

Advance pipeline candidatesShort term

Clinical and regulatory progress is the main driver of value in a development-stage biotech model.

Secure financingShort term

Biopharmaceutical development requires ongoing capital before product revenue exists.

Preserve intellectual propertyMedium term

Patent and proprietary asset protection supports partnering leverage and future commercialization.

Geography

ZyVersa is headquartered in the United States and its business is organized from a U.S. corporate base. As a development-stage pharmaceutical company, its operating footprint is primarily tied to U.S. capital markets, U.S.-based management, and any clinical or research activities conducted through external partners.

Risks

ZyVersa faces the typical risks of a development-stage biotech company: clinical failure, regulatory delay, and dependence on external financing before any product revenue is established. The company also disclosed market-structure risks tied to Nasdaq delisting and OTCQB quotation, which can reduce liquidity, limit investor access, and increase share-price volatility.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Nasdaq delisting and OTC trading risk2Penny stock classification4Regulatory and tax changes5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: Critical

    Drug candidates may not meet endpoints or safety requirements, which can eliminate pipeline value.

    Exposure: Inflammatory and renal disease programs

  2. Nasdaq delisting and OTC trading riskImpact: HighLikelihood: High

    Reduced exchange access can lower liquidity, widen spreads, and impair investor demand.

    Exposure: Common stock trading on OTCQB

  3. Financing and dilution riskImpact: High

    The company relies on external capital to fund R&D before commercial revenues exist.

    Exposure: Equity issuance and related financing arrangements

  4. Penny stock classificationImpact: MediumLikelihood: High

    Broker-dealer suitability and sales practice rules can restrict trading and marketability.

    Exposure: Public market trading in common stock

  5. Regulatory and tax changesImpact: LowLikelihood: Medium

    Changes in laws or operations can affect compliance burden and effective tax rate.

    Exposure: U.S. corporate and tax environment

Accounting

Judgemental items
Equity financing and warrant accounting

Recent financing arrangements may require fair value measurement and careful classification between equity and liabilities.

Impact: Can create non-cash gains/losses and affect dilution

Stock-based compensation

Biotech issuers often use equity awards to conserve cash, increasing non-cash operating expense.

Impact: Affects reported operating loss and share count

Fair value measurements

Preferred stock, warrants, or other embedded features may need periodic revaluation.

Impact: Can introduce earnings volatility

Going concern assessment

Development-stage companies must assess whether available capital is sufficient to fund operations.

Impact: May influence disclosure and investor perception

Similar listed companies

Publicly listed companies with a comparable business focus.

Zymeworks Inc.

ZYME · Pharmaceutical Preparations

Zai Lab Ltd

ZLAB · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Provectus Biopharmaceuticals, Inc.

PVCT · Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Centessa Pharmaceuticals plc

Pharmaceutical Preparations

Last updated: 24/09/2026